Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LIGAND PHARMACEUTICALS INC Director's Dealing 2017

Mar 1, 2017

31289_dirs_2017-02-28_92b401f7-6d88-4fd5-987f-6ce50aed2cc3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-08-06

Reporting Person: Korenberg Matthew E (VP, Finance and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-08-06 Common Stock F 609 $123.3 Disposed 9457 Direct
2017-02-15 Common Stock F 391 $104.28 Disposed 9106 Direct
2017-02-24 Common Stock A 3450 $0.0 Acquired 12556 Direct
2017-02-24 Common Stock F 1051 $100.38 Disposed 11505 Direct
2017-02-24 Common Stock A 3567 $0.0 Acquired 15072 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-02-24 Employee Stock Option (right to buy) $100.38 A 15225 Acquired 2027-02-24 Common Stock (15225) Direct

Footnotes

F1: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 08/06/2015.

F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016.

F3: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2016. On February 24, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.

F4: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs.

F5: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Optioned Shares per month thereafter.